跳到正文
原文
BioPharma Dive· Kristin Jensen·· 2026-10-01AI 评分42

HHS 启动新计划以加速临床试验并应对中国竞争

HHS kicks off new programs to speed clinical trials as Chinese competition looms

AI 导读

美国卫生与公众服务部(HHS)周三启动了“Surpass”和ARPA-H新计划,旨在加速美国药品研发并应对来自澳大利亚和中国的竞争。这些项目计划提供资金支持创新提案,建设数据基础设施以加快临床试验入组,并开发“无阶段设计引擎”来取代传统的分阶段试验体系。官方指出,新开发药物耗时约 10 年且成本高达 10 亿至 20 亿美元,通过创新有望缩短一半时间并降低 10 倍成本。

正文

An article from site logo

Dive Brief

The department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.

Published Oct. 1, 2026

By Kristin Jensen

A picture of the exterior of the US Department of Health and Human Services. In front of the building is a black sign designating the building's name.

The exterior of the U.S. Department of Health and Human Service in Washington, DC. Alex Wong via Getty Images

Dive Brief:

  • The Trump administration on Wednesday unveiled new efforts to speed U.S. pharmaceutical research as competition from foreign countries increases.
  • The programs include “Surpass,” which “envisions a future in which clinical development operates as a continuous learning system rather than a sequence of disconnected trials.” The five-year program is soliciting proposals from teams with innovative ideas in three major areas while offering government funding and support.
  • At the same time, the Advanced Research Projects Agency for Health — or ARPA-H — is kickstarting three projects designed to speed clinical trial enrollment, build “nationwide data infrastructure” and better empower patients involved in research. “These efforts will address multiple barriers that slow clinical trial development today,” the Health and Human Services Department said in a statement.

Dive Insight:

Health officials are trying to make the U.S. more enticing as a location for clinical trials as countries including Australia and China increasingly attract pharmaceutical research. China’s share of global Phase 1 clinical trials surpassed the U.S. for the first time in 2021, and in 2024 the country registered a higher total of all registered clinical studies for the first time, according to an HHS memo released last month. Australia has also seen gains; it has one of the highest trials-per-capita rates in the world.

Compared with the U.S., China and Australia offer speed, lower costs and less regulatory burden. In Australia, drugmakers can begin clinical trials between six and 12 months earlier than in the U.S., and studies may cost half as much, according to a recent thinktank report. China, meanwhile, has proven especially attractive to pharmaceutical companies, with licensing deals booming.

The latest U.S. government efforts come on the heels of the Food and Drug Administration’s Operation Trialblazer, which is designed to speed up early clinical trials for new medicines through the use of qualified research institutions. And it comes days after the leaders of nine European pharmaceutical makers warned their industry is also quickly losing ground to China.

A main focus for the Surpass project is on building a “phaseless design engine” instead of the current system, which requires significant regulatory coordination between phases of research. The program is also looking for teams that can develop a system that offers real-time or on-demand analysis for faster decision making and an “agentic operations layer” to automate many research activities.

Today, the development of a new drug takes about 10 years and costs between $1 billion and $2 billion, with sponsors ultimately failing more than 90% of the time, according to HHS documents. With innovations, it may be possible to cut timelines in half and achieve a 10-fold reduction in costs, Daria Fedyukina, the Surpass program manager, told Axios.

来源:BioPharma Dive · biopharmadive.com